Can we modify transplant outcome by improving lymphocyte recovery?

Cytotherapy

Volumn 13, Issue 8, 2011, Pages 900-902

  Savani, Bipin N ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

lymphocyte recovery; survival; transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; PLERIXAFOR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RELAPSE; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOKINE INDUCED KILLER CELL; CYTOTOXIC T LYMPHOCYTE; DRUG MEGADOSE; FEBRILE NEUTROPENIA; GRAFT VERSUS LEUKEMIA EFFECT; HELPER CELL; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LYMPHOCYTE; LYMPHOCYTE COUNT; MEMORY CELL; MORTALITY; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; NOTE; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 80051880837     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.603220     Document Type: Note

References (19)

1. +- lymphocytes on day 5 after high-dose melphalan for multiple myeloma predict a low risk of infections during severe neutropenia and are associated with the number of reinfused T lymphocytes of the autologous stem cell graft. Cytotherapy. 2011 May 23. [Epub ahead of print].
2. Barrett AJ, Savani BN. Does chemotherapy modify the immune surveillance of hematological malignancies? Leukemia. 2009;23:53-8.
3. Le Blanc K, Barrett AJ, Schaffer M, Hägglund H, Ljungman P, Ringdén O, et al. Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. Biol Blood Marrow Transplant. 2009;15:1108-15.
4. Savani BN, Mielke S, Rezvani K, Montero A, Yong AS, Wish L, et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:1216-23. (Pubitemid 47413017)
5. Tedeschi SK, Jagasia M, Engelhardt BG, Domm J, Kassim AA, Chinratanalab W, et al. Early lymphocyte reconstitution is associated with improved transplant outcome after cord blood transplantation. Cytotherapy. 2011;13:78-82.
6. Porrata LF, Markovic SN. Autograft mediated adoptive immunotherapy of cancer in the context of autologous stem cell transplantation. World J Clin Oncol. 2010;1:29-34.
7. Burke MJ, Vogel RI, Janardan SK, Brunstein C, Smith AR, Miller JS, et al. Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. Biol Blood Marrow Transplant. 2011;17:831-40.
8. Ege H, Gertz MA, Markovic SN, Lacy MQ, Dispenzieri A, Hayman SR, et al. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. Br J Haematol. 2008;141:792-8. (Pubitemid 351724861)
9. Matthews K, Lim Z, Pearce L, Pagliuca A, Alejandro Madrigal J, Mufti GJ, et al. Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab. Br J Haematol. 2010;149:879-89.
10. Stover DG, Reddy VK, Shyr Y, Savani BN, Reddy N. Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma. Bone Marrow Transplant. 2011 Feb 28. [Epub ahead of print].
11. Saliba RM, Komanduri KV, Giralt S, de Souza J, Patah P, Oran B, et al. Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone Marrow Transplant. 2009;43:685-92.
12. Meehan KR, Talebian L, Wu J, Hill JM, Szczepiorkowski ZM, Sentman CL, Ernstoff MS. Immune mobilization of autologous blood progenitor cells: direct infl uence on the cellular subsets collected. Cytotherapy. 2010;12:1013-21.
13. +(- ) cells mobilized by G-CSF and plerixafor. Exp Hematol. 2011 Apr 15. [Epub ahead of print].
14. Condomines M, Quittet P, Lu ZY, Nadal L, Latry P, Lopez E, et al. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. J Immunol. 2006;176:6631-9. (Pubitemid 43787846)
15. Eksioglu EA, Kielbasa J, Eisen S, Reddy V. Granulocyte - macrophage colony-stimulating factor increases the proportion of circulating dendritic cells after autologous but not afterallogeneic hematopoietic stem cell transplantation. Cytotherapy. 2011 May 24. [Epub ahead of print].
16. Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C, et al. Randomized trial of fi lgrastim versus chemotherapy and fi lgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood. 2001;98:2059-64.
17. Satwani P, van de Ven C, Ayello J, Cairo D, Simpson LL, Baxi L, Cairo MS. Interleukin (IL)-15 in combination with IL-2, fms-like tyrosine kinase-3 ligand and anti-CD3 signifi cantly enhances umbilical cord blood natural killer (NK) cell and NK-cell subset expansion and NK function. Cytotherapy. 2011;13:730-8.
18. Alpdogan O, van den Brink MR. IL-7 and IL-15: therapeutic cytokines for immunodefi ciency. Trends Immunol. 2005; 26:56-64. (Pubitemid 40051993)
19. Kang Y, Chen BJ, Deoliveira D, Mito J, Chao NJ. Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model. PLoS One. 2010;5:e11316.